Abstract
Objectives
Although implantable left ventricular assist device use as a bridge to heart transplantation is increasing, its permanent use as destination therapy is not permitted in Japan. This retrospective review assessed early and mid-term outcomes of implantable continuous-flow left ventricular assist device compared with extracorporeal pulsatile-flow left ventricular assist device implantation. Issues regarding left ventricular assist device as destination therapy are discussed.
Methods
From January 2009 to September 2013, 72 patients underwent left ventricular assist device implantation at our institute. Forty patients were supported by extracorporeal pulsatile-flow left ventricular assist devices (ex-VAD group) and 32 patients with implantable continuous-flow left ventricular assist devices (im-VAD group).
Results
The median duration of ventricular assist device support was 563 days. The actuarial survival rates at 1 and 3 years were 92.3 and 79.2 % in the ex-VAD group and 96.4 and 72.3 % in the im-VAD group, respectively. Approximately 50 % of patients in both groups developed cerebrovascular complications within 1 year postoperatively. Six months post-implantation, almost 90 % of the ex-VAD group patients suffered exit-site infection compared with about 50 % in the im-VAD group. Readmission rate was 1.74 per patient-year; major causes were driveline exit-site infection (52 %) and cerebrovascular complication (14 %).
Conclusions
Early and mid-term outcomes were satisfactory after both extracorporeal pulsatile-flow left ventricular assist device and implantable continuous-flow left ventricular assist device implantation, although a considerable level of postoperative complications was observed. More data after left ventricular assist device surgery are needed to enable its consideration as a destination therapy option in Japan.
Similar content being viewed by others
References
Miller LW, Pagani FD, Russel SD, John R, Boyle AJ, Aaronson KD, et al. Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med. 2007;357:885–96.
Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361:2241–51.
Peura JL, Colvin-Adams M, Francis GS, Grady KL, Hoffman TM, Jessup M, et al. Recommendation for the use of mechanical circulatory support: device strategies and patient selection: a scientific statement from the American Heart Association. Circulation. 2012;126:2648–67.
Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001;345:1435–43.
Kirklin JK, Naftel DC, Kormos RL, Stevenson LW, Pagani FD, Miller MA, et al. Fifth INTERMACS annual report: risk factor analysis from more than 6000 mechanical circulatory support patients. J Heart Lung Transplant. 2013;32:141–56.
Kirklin JK, Naftel DC, Pagani FD, Kormos RL, Stevenson LW, Blume ED, et al. Sixth INTERMACS annual report: a 10000- patient database. J Heart Lung Transplant. 2014;33:555–64.
Pharmaceuticals and Medical Devices Agency. J-MACS statistical report. 2014. http://www.pmda.go.jp/files/000147613.pdf#page=1&r=s&r=s.
Toda K, Fujita T, Kobayashi J, Shimahara Y, Kitamura S, Seguchi O, et al. Impact of preoperative percutaneous cardiopulmonary support on outcome following left ventricular assist device implantation. Circ J. 2012;76:88–95.
Suwa H, Seguchi O, Fujita T, Murata Y, Hieda M, Watanabe T, et al. Paracorporeal ventricular assist device as a bridge to transplant candidacy in the era of implantable continuous-flow ventricular assist device. J Artif Organs. 2014;17:16–22.
Kitamura S. Heart transplantation in Japan: a critical appraisal for the results and future prospects. Gen Thorac Cardiovasc Surg. 2012;60:639–44.
Lahpor J, Khaghani A, Hetzer R, Pavie A, Friedrich I, Sander K, et al. European results with a continuous-flow ventricular assist device for advanced heart-failure patients. Eur J Cardiothorac Surg. 2010;37:357–61.
Starling RC, Moazami N, Silvestry SC, Ewald G, Rogers JG, Milano CA, et al. Unexpected abrupt increase in left ventricular assist device thrombosis. N Engl J Med. 2014;370:33–40.
Backes D, van den Bergh WM, van Duijn AL, Lahpor JR, van Dijk D, Slooter AJ. Cerebrovascular complications of left ventricular assist devices. Eur J Cardiothorac Surg. 2012;42:612–20.
Rajagopal K, Daneshmand MA, Patel CB, Ganapathi AM, Schechter MA, Rogers JG, et al. Natural history and clinical effect of aortic valve regurgitation after left ventricular assist device implantation. J Thorac Cardiovasc Surg. 2013;145:1373–9.
Cowger J, Pagani FD, Haft JW, Romano MA, Aaronson KD, Kolias TJ. The development of aortic insufficiency in left ventricular assist device-supported patients. Circ Heart Fail. 2010;3:668–74.
Hata H, Fujita T, Ishibashi-Ueda H, Nakatani T, Kobayashi J. Pathological analysis of the aortic valve after long-term left ventricular assist device support. Eur J Cardiothorac Surg. 2014;46:193–7.
Park SJ, Liao KK, Segurola R, Madhu KP, Miller LW. Management of aortic insufficiency in patients with left ventricular assist devices: a simple coaptation stitch method (Park’s stitch). J Thorac Cardiovasc Surg. 2004;127:264–6.
Fujita T, Kobayashi J, Hata H, Seguchi O, Sato T, Yanase M, et al. Aortic valve closure for rapidly deteriorated aortic insufficiency after continuous flow left ventricular assist device implantation. J Artif Organs. 2013;16:98–100.
Hasin T, Marmor Y, Kremens W, Topilsky Y, Severson CJ, Schirger JA, et al. Readmission after implantation of axial flow left ventricular assist device. J Am Coll Cardiol. 2013;61:153–63.
Kimura M, Kinoshita O, Nawata K, Nishimura T, Hatano M, Imamura T, et al. Midterm outcome of implantable left ventricular assist devices as a bridge to transplantation: single-center experience in Japan. J Cardiol. 2014;. doi:10.1016/j.jjcc.2014.06.007.
Kyo S, Minami T, Nishimura T, Gojo S, Ono M. New era for therapeutic strategy for heart failure: destination therapy by left ventricular assist device. J Cardiol. 2012;59:101–9.
Yamakawa M, Kyo S, Yamakawa S, Ono M, Kinugawa K, Nishimura T. Destination therapy: the new gold standard treatment for heart failure patients with left ventricular assist devices. Gen Thorac Cardiovasc Surg. 2013;61:111–7.
Nishimura T. Current status of extracorporeal ventricular assist devices in Japan. J Artif Organs. 2014;17:211–9.
Conflict of interest
The authors have declared that no conflict of interest exists.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hata, H., Fujita, T., Shimahara, Y. et al. Early and mid-term outcomes of left ventricular assist device implantation and future prospects. Gen Thorac Cardiovasc Surg 63, 557–564 (2015). https://doi.org/10.1007/s11748-015-0538-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11748-015-0538-7